- Nobias Therapeutics, a biotech leader, joins NVIDIA Inception program.
- Nobias pioneers AI-based deep phenotyping for advanced therapeutics.
- The Nobias Workbench™ accelerates target finding and therapy development.
- Partnership with NVIDIA enhances access to AI resources and technologies.
- Nobias integrates generative AI and graph convolutional networks for molecule discovery.
- Headquarters in Silicon Valley taps into a rich talent pool; maintains a presence in Philadelphia.
Main AI News:
Nobias Therapeutics, a pioneering biotechnology enterprise specializing in artificial intelligence (AI)-driven deep phenotyping methodologies for advanced therapeutic exploration, has proudly revealed its recent inclusion in NVIDIA Inception, an esteemed program fostering startups transforming industries through technological breakthroughs.
Under the stewardship of distinguished professionals in big data and AI, Nobias has engineered a bespoke, scalable AI framework dubbed the Nobias Workbench™. This innovative platform distills crucial disease determinants and optimal intervention points from extensive clinical and genetic data repositories. Empowered by the Nobias Workbench™, the company expedites target identification and molecular exploration, facilitating the advancement of groundbreaking therapies across a spectrum of disorders, including its pioneering breakthrough treatments for rare pediatric ailments.
Sam Inala, Vice President of Engineering at Nobias Therapeutics, emphasized, “As innovators dedicated to harnessing cutting-edge AI and machine learning models to revolutionize drug discovery and development, Nobias is privileged to join NVIDIA Inception. This partnership augments our capacity to pioneer novel therapeutics for patients confronting limited or scarce treatment avenues. Access to NVIDIA Deep Learning Institute workshops, coupled with preferential pricing on critical technologies such as NVIDIA GPUs, will propel the evolution of Nobias and the Nobias Workbench™. We are eager to leverage this collaboration to engage with top-tier experts and fellow AI-centric enterprises.”
Nobias has introduced a suite of AI-driven tools within its Workbench, integrating contemporary methodologies like generative AI, expansive language models, and graph convolutional networks. These offerings embrace an iterative, hypothesis-centered methodology, facilitating target identification and molecule generation. Collaborating with NVIDIA experts and availing preferential rates on NVIDIA hardware, software, and Deep Learning Institute resources, Nobias is poised to elevate its capacity for prototyping, innovation, and technology deployment in the realm of drug discovery.
In 2023, Nobias established its headquarters in Silicon Valley, bolstering its operations with NVIDIA hardware while initiating the development of its AI platform. Situated amidst Silicon Valley’s vibrant ecosystem, Nobias capitalizes on a rich talent pool in technology and biotechnology, positioning itself for sustained expansion. Concurrently, the company maintains a robust presence in Philadelphia, its city of origin, underscoring its commitment to innovation and growth.
Conclusion:
Nobias Therapeutics’ collaboration with NVIDIA through the Inception program signifies a strategic move towards leveraging AI-driven innovation in biotechnology. By harnessing NVIDIA’s resources and expertise, Nobias strengthens its position as a frontrunner in developing novel therapeutics, which could potentially disrupt the market landscape with more efficient drug discovery processes and enhanced treatment options for patients.
